Management of Myelodysplastic Syndromes
Authors: RICHARD A. LARSON
Journal: Annals of Internal Medicine (1985)

Editorials1 July 1985Management of Myelodysplastic SyndromesRICHARD A. LARSON, M.D.RICHARD A. LARSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-1-136 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by anemia, neutropenia, or thrombocytopenia in various combinations (1, 2). The bone marrow is usually hypercellular or at least normocellular and may contain increased numbers of immature cells. The diagnosis rests on the finding of characteristic morphologic abnormalities in the peripheral blood as well as in the marrow. Among the commonest abnormalities are asynchrony of nuclear and cytoplasmic maturation, ringed sideroblasts, nuclear budding or premature karyorrhexis of erythrocyte nuclei, hypogranulated myeloid precursors, hyposegmented or hypersegmented nuclei in neutrophils, and micromegakaryocytes or megakaryocytes with a single large nucleus...References1. BENNETTCATOVSKYDANIEL JDM. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-99. CrossrefMedlineGoogle Scholar2. GREENBERG P. The smoldering myeloid leukemic states: clinical and biological features. Blood. 1983;61:1035-44. CrossrefMedlineGoogle Scholar3. PUGHPEARSONVARDIMANROWLEY WMJJ. Philadelphia chromosome-negative chronic myelogenous leukemia: a morphological reassessment. Br JHaematol. 1985;60. (In press). Google Scholar4. JACOBSCORNBLEETVARDIMANROWLEY RMJJ. Correlation between morphologic subtype, clinical characteristics, and cytogenetic abnormalities in patients with de novo dysmyelopoietic syndromes. [Abstract]. Blood. 1984;64 (suppl. 1):147a. MedlineGoogle Scholar5. TRICOTDE WOLF-PEETERSVLIETINCKVERWILGHEN GCRR. Bone marrow histology in myelodysplastic syndromes: II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol. 1984;58:217-25. CrossrefMedlineGoogle Scholar6. GOLDCONJALKAPELUS EML. Marrow cytogenetic and cell-culture analyses of the myelodysplastic syndromes: insights to pathophysiology and prognosis. J Clin Oncol. 1983;1:627-34. CrossrefMedlineGoogle Scholar7. KERKHOFSHAGEMEIJERLEEKSMA HAC. The 5q— chromosome abnormality in haematological disorders: a collaborative study of 34 cases from The Netherlands. Br J Haematol. 1982;52:365-81. CrossrefMedlineGoogle Scholar8. MARTINBALDOCKGHONEIMCHILD SSAJ. Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol. 1983;36:1120-8. CrossrefMedlineGoogle Scholar9. BAGBYGABOURELLINMAN GJJ. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques. Ann Intern Med. 1980;92:55-8. LinkGoogle Scholar10. MERTELSMANNTHALERTO RHL. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood. 1980;56:773-81. CrossrefMedlineGoogle Scholar11. APPELBAUMSTORBRAMBERG FRR. Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med. 1984;100:689-93. LinkGoogle Scholar12. WISCHGRIFFINKUFE JJD. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983;309:1599-602. CrossrefMedlineGoogle Scholar13. TRICOTDE BOCKDEKKER GRA. Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br J Haematol. 1984;58:231-40. CrossrefMedlineGoogle Scholar14. ELLISONHOLLANDWEIL RJM. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507-23. CrossrefMedlineGoogle Scholar15. WINTERVARIAKOJISGAYNORLARSONMILLER JDERK. Low-dose cytosine arabinoside therapy in myelodysplastic syndromes and acute leukemia. Cancer. 1985. (In press). CrossrefMedlineGoogle Scholar16. FLYNNMILLERWEISDORF PWD. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 1983;62:1211-7. CrossrefMedlineGoogle Scholar17. BESAGRANICKITRINOWELL EJLP. Complete hematologic and cytogenetic remission in a patient with dysmyelopoietic syndrome treated with 13-cis-retinoic acid [Abstract]. Blood. 1983;62(suppl 1):199a. Google Scholar18. GOLDMERTELSMANNITRI ERL. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep. 1983;67:981-6. MedlineGoogle Scholar19. DESFORGES J. Cytarabine: low-dose, high-dose, no dose [Editorial]? N Engl J Med. 1983;309:1637-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Chicago Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAUTOLOGOUS BONE MARROW TRANSPLANTATION IN ACUTE LEUKEMIAHeterogeneity of acquired idiopathic sideroblastic anaemia (AISA)Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II TrialTreatment of resistant acute myeloid leukemiaDanazol treatment of myelodysplastic syndromesInfection in the myelodysplastic syndromesInfection in the myelodysplastic syndromesAcute myelogenous leukaemia in childrenPrimary Acquired Myelodysplastic SyndromesCombination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromesManagement of myelodysplastic syndromesCarmustine and MyelodysplasiaSTUART M. LICHTMAN, M.D., PHILIP SCHULMAN, M.D. 1 July 1985Volume 103, Issue 1Page: 136-138KeywordsAnemiaBloodBone marrowCellsHematopoietic stem cellsMegakaryocytesMyelodysplastic syndromesNeutropeniaNeutrophils Issue Published: 1 July 1985 PDF downloadLoading ...